|
US3854480A
(en)
|
1969-04-01 |
1974-12-17 |
Alza Corp |
Drug-delivery system
|
|
US4279909A
(en)
|
1980-02-13 |
1981-07-21 |
Fujisawa Pharmaceutical Co., Ltd. |
Antiallergic method
|
|
US4675189A
(en)
|
1980-11-18 |
1987-06-23 |
Syntex (U.S.A.) Inc. |
Microencapsulation of water soluble active polypeptides
|
|
US4452775A
(en)
|
1982-12-03 |
1984-06-05 |
Syntex (U.S.A.) Inc. |
Cholesterol matrix delivery system for sustained release of macromolecules
|
|
US5075109A
(en)
|
1986-10-24 |
1991-12-24 |
Southern Research Institute |
Method of potentiating an immune response
|
|
US5133974A
(en)
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
|
US5407686A
(en)
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
|
US5736152A
(en)
|
1995-10-27 |
1998-04-07 |
Atrix Laboratories, Inc. |
Non-polymeric sustained release delivery system
|
|
US6492428B1
(en)
|
2000-07-26 |
2002-12-10 |
The Picower Institute For Medical Research |
Compounds having MIF antagonist activity
|
|
US6197749B1
(en)
|
1997-10-29 |
2001-03-06 |
Ajinomoto Co., Inc. |
Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
|
|
CA2413878A1
(en)
|
2000-06-20 |
2001-12-27 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
|
|
JP2005522457A
(ja)
|
2002-02-26 |
2005-07-28 |
ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート |
脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
|
|
WO2005026134A1
(en)
|
2003-09-17 |
2005-03-24 |
Novartis Ag |
Organic compounds
|
|
US20050287664A1
(en)
|
2004-05-27 |
2005-12-29 |
Ming-Ji Fann |
Cellular proliferation control factors
|
|
US20060148715A1
(en)
|
2004-12-20 |
2006-07-06 |
Baylor College Of Medicine |
Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands
|
|
US20100035793A1
(en)
|
2005-07-27 |
2010-02-11 |
Cheh Peng Lim |
Modulators
|
|
US20070203236A1
(en)
|
2006-01-11 |
2007-08-30 |
Smith Jeffrey W |
Novel antagonists of the human fatty acid synthase thioesterase
|
|
CA2636909A1
(en)
|
2006-01-13 |
2007-07-26 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production with tanshinones
|
|
WO2007136858A2
(en)
|
2006-05-19 |
2007-11-29 |
H. Lee Moffitt Cancer Center & Research Institute |
Small molecule inhibitors of stat3 with anti-tumor activity
|
|
US20090264353A1
(en)
|
2007-10-19 |
2009-10-22 |
Santaris Pharma A/S |
Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
|
|
HRP20160625T1
(hr)
*
|
2007-09-10 |
2016-08-12 |
Boston Biomedical, Inc. |
Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
|
|
WO2009038784A1
(en)
|
2007-09-21 |
2009-03-26 |
Amgen Inc. |
Triazole fused heteroaryl compounds as p38 kinase inhibitors
|
|
EP2299999B1
(en)
*
|
2008-06-04 |
2017-08-16 |
Baylor College Of Medicine |
Stat3 inhibitors
|
|
GB2463514C
(en)
|
2008-09-11 |
2018-09-26 |
Galapagos Nv |
Imidazolidine compounds and uses therefor
|
|
WO2010080581A2
(en)
|
2008-12-19 |
2010-07-15 |
The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno |
Valproic acid, derivatives, analogues, and compositions including same and methods for their therapeutic use
|
|
US8557805B2
(en)
|
2008-12-29 |
2013-10-15 |
Takeda Pharmaceutical Company Limited |
Fused ring compound and use thereof
|
|
US9891213B2
(en)
|
2009-01-12 |
2018-02-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Granulocyte-based methods for detecting and monitoring immune system disorders
|
|
CA2781706A1
(en)
*
|
2009-11-24 |
2011-06-03 |
The Ohio State University |
Transcription factor inhibitors and related compositions, formulations and methods
|
|
FR2962649B1
(fr)
|
2010-07-19 |
2025-10-24 |
Conservatoire Nat Arts Et Metiers |
Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
|
|
US20140371188A1
(en)
|
2011-11-23 |
2014-12-18 |
University Of Iowa Research Foundation |
Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy
|
|
EP2708535A1
(en)
|
2012-05-11 |
2014-03-19 |
Les Laboratoires Servier |
Agents for treating disorders involving modulation of ryanodine receptors
|
|
CN102766103B
(zh)
*
|
2012-07-24 |
2014-12-10 |
齐鲁制药有限公司 |
2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途
|
|
AU2014290363B2
(en)
*
|
2013-07-18 |
2019-02-21 |
Baylor College Of Medicine |
Methods and compositions for treatment of fibrosis
|
|
AU2014290368B2
(en)
|
2013-07-18 |
2019-07-11 |
Baylor College Of Medicine |
Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
|
|
US20150031714A1
(en)
|
2013-07-18 |
2015-01-29 |
Baylor College Of Medicine |
Methods and compositions for prevention of allergic reaction
|
|
WO2017083719A1
(en)
*
|
2015-11-13 |
2017-05-18 |
William Marsh Rice University |
Transition metal free methods of synthesis of biaryl compounds
|
|
JP7411315B2
(ja)
*
|
2018-04-19 |
2024-01-11 |
トゥヴァルディ セラピューティクス，インク． |
Ｓｔａｔ３阻害剤
|
|
US11026905B2
(en)
*
|
2018-04-19 |
2021-06-08 |
Tvardi Therapeutics, Inc. |
STAT3 inhibitors
|
|
JP2023520273A
(ja)
*
|
2020-01-24 |
2023-05-17 |
トゥヴァルディ セラピューティクス，インク． |
治療化合物、製剤、およびその使用
|